Last reviewed · How we verify

NCT03193229

MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes

Completed NA Last updated 16 October 2018
What this trial tests

NA trial testing MapTrek in Pre Diabetes in 430 participants. Completed in 4 May 2018.

Timeline
15 May 2017
Primary endpoint
2 April 2018
4 May 2018

Quick facts

Lead sponsorPhilip Polgreen
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment430
Start date15 May 2017
Primary completion2 April 2018
Estimated completion4 May 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Philip Polgreen

Who can join

Adults 21 to 80, any sex, with Pre Diabetes or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching objective of our work is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for type 2 diabetes. The objective of this study is to pilot test MapTrek, a text-messaging based intervention.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Gamifying accelerometer use increases physical activity levels of individuals pre-disposed to type II diabetes.
    Francis SL, Simmering JE, Polgreen LA, Evans NJ, et al · · 2021 · cited 9× · PMID 34178586 · DOI 10.1016/j.pmedr.2021.101426

Verify or expand the search:

Other trials of MapTrek

Trials testing the same drug.

Other recruiting trials for Pre Diabetes

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03193229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing